GLP1R and obesity due to melanocortin 4 receptor deficiency: Pharmacological treatments, including GLP-1 receptor agonists and other anti-obesity medications, offer promise for sustained weight loss and OSA improvement, but real-world data indicate that their effectiveness is often limited by side effects, high cost, and suboptimal long-term adherence (39, 96).